Blog
ChemAIRS® vs Reaxys® vs SYNTHIA®
Compare ChemAIRS®, Reaxys®, and SYNTHIA® for computer-aided synthesis planning: what each tool does, where they overlap, and how to choose.
Oveporexton (TAK-861): A First-in-Class Orexin Agonist for Narcolepsy Type 1 and Its ChemAIRS® Retrosynthesis
Retrosynthetic analysis of oveporexton (TAK-861), the first-in-class OX2R agonist for narcolepsy type 1, now under FDA Priority Review, planned with ChemAIRS®.
Synthesis of Daraxonrasib (RMC-6236): ChemAIRS® Retrosynthetic Analysis Behind the FDA-Accepted RAS(ON) Inhibitor
Synthesis of daraxonrasib (RMC-6236): ChemAIRS® proposes discovery and process routes for the RAS(ON) inhibitor now under FDA review.
ChemAIRS®-Proposed Synthesis of Zidesamtinib (NVL-520), the Newly Approved TRK-Sparing ROS1 Inhibitor
ChemAIRS-proposed synthesis of zidesamtinib (NVL-520): two routes to the macrocyclic ROS1 inhibitor just approved for previously treated ROS1+ NSCLC.
ChemAIRS®-Proposed Synthesis of Sonrotoclax (BGB-11417): From Nine Steps to Four, With Late-Stage Head Group Installation
ChemAIRS® generated a route to sonrotoclax (BGB-11417) that cuts the disclosed synthesis from nine steps to four, by installing the P2 head group last instead of carrying it through the whole sequence.